Ticker Deep Dive · Published 2026-10-02 · 5 min read

CytoDyn Inc. (CYDY): FDA Clinical Holds, SEC Subpoenas & Share Capital Audit

CytoDyn (CYDY) is one of the most widely followed retail biotech stocks on the OTCQB. This forensic breakdown analyzes its authorized share expansions, convertible debt obligations, and FDA regulatory milestones.

Key Takeaways

Repeated shareholder votes to raise authorized shares from 450M up to over 1.35 billion shares to fund clinical trials.
High dependency on promissory notes with warrant coverage to maintain working capital without institutional bank credit lines.
Always verify active FDA clinical trial status and lifting of clinical holds directly via clinicaltrials.gov rather than corporate press releases.

Analyze CYDY Live (3-Year Financials & Dilution Check) →

1. Biotech Share Creep & Cash Burn

Development-stage biotechnology companies on the OTC markets have zero product revenue and burn millions each quarter. CYDY's capital history is a classic case of share expansion: each round of trial funding increases the denominator, requiring subsequent rallies to move larger float amounts.

Retail investors must distinguish between clinical progress announcements and financing S-3 registration statements that register millions of newly minted shares for sale.

2. Legal & Regulatory Due Diligence

Prior executive leadership faced DOJ and SEC scrutiny regarding promotional disclosures. Always inspect Form 10-K Item 3 (Legal Proceedings) to assess ongoing litigation reserves.

Frequently Asked Questions

Can CYDY uplist back to NASDAQ?
Uplisting requires meeting the NASDAQ Capital Market minimum bid price of $4.00 (or $3.00 under certain rules) and minimum shareholders equity of $5,000,000, which typically requires a reverse stock split.

Not Financial Advice: Informational and educational purposes only. Never gamble money you cannot afford to lose, and always spend at least 1 hour investigating filings before buying any penny stock.